UNIGE document Scientific Article - Case report
previous document  unige:55144  next document
add to browser collection

Three new cases of late-onset cblC defect and review of the literature illustrating when to consider inborn errors of metabolism beyond infancy

Huemer, Martina
Scholl-Bürgi, Sabine
Beer, Ronny
Seppi, Klaus
Fowler, Brian
Baumgartner, Matthias R
show hidden authors show all authors [1 - 9]
Published in Orphanet Journal of Rare Diseases. 2014, vol. 9, no. 1, p. 161
Abstract BackgroundThe cblC defect is a rare inborn error of intracellular cobalamin metabolism. Biochemical hallmarks are elevated homocysteine and low methionine in plasma accompanied by methylmalonic aciduria. Due to the heterogeneous clinical picture, patients with the late-onset form of the disease (onset >12 months) come to the attention of diverse medical specialists, e.g. paediatricians, neurologists, nephrologists, psychiatrists or haematologists. The report reviews the published clinical data and adds three new cases to raise awareness for this severe but often treatable disease.MethodsThe Pubmed and the Cochrane databases were searched for clinical reports on cblC patients and three unreported cases are presented to illustrate the clinical spectrum.ResultsReports on 58 cases (30 females, 22 males, 6¿=¿no information) and the three new cases underlined the clinical heterogeneity of the disease. Time between first symptoms and diagnosis ranged from three months to more than 20 years. Haemolytic uraemic syndrome and pulmonary hypertension were main presenting symptoms in preschool children. In older children / adolescents, psychiatric symptoms, cognitive impairment, ataxia and myelopathy were frequently observed while thromboembolic events and glomerulopathies were almost exclusively seen in adults. Brain atrophy, white matter lesions and myelopathy were frequently encountered. The majority of patients showed marked biochemical and clinical response to treatment with parenteral hydroxocobalamin combined with oral betaine, folate, carnitine and rarely methionine. The course was less favourable in late treated or untreated patients.ConclusionsThe late-onset cblC defect is a rare disease and unfortunately, diagnosis is often delayed. Raising awareness for this disorder can significantly improve patients¿ outcome and perspective by timely initiation of targeted treatment. Newborn screening (NBS) for the cblC defect might be of benefit especially for late-onset patients since treatment seems efficient when initiated before irreversible organ damage. In general, inborn errors of metabolisms should be considered in unexplained medical cases at any age, especially in patients with multisystemic disease. More specifically, total homocysteine in plasma and methylmalonic acid in urine / plasma should be measured in unexplained neurologic, psychiatric, renal, haematologic and thromboembolic disease.
PMID: 25398587
Full text
Article (Published version) (431 Kb) - public document Free access
Research group Pathogénèse du syndrome néphrotique idiopathique de l'enfant (180)
(ISO format)
HUEMER, Martina et al. Three new cases of late-onset cblC defect and review of the literature illustrating when to consider inborn errors of metabolism beyond infancy. In: Orphanet Journal of Rare Diseases, 2014, vol. 9, n° 1, p. 161. doi: 10.1186/s13023-014-0161-1 https://archive-ouverte.unige.ch/unige:55144

407 hits



Deposited on : 2015-04-07

Export document
Format :
Citation style :